查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1676680

生物共轭市场：按生物共轭类型、按产品、按技术、按类型、按最终用户、按应用、按治疗领域 - 2025-2030 年全球预测

Bioconjugation Market by Bioconjugation Type, Offering, Technique, Type, End User, Applications, Therapeutic Areas - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年生物共轭市场价值将达81.3亿美元，2024年将成长至90.6亿美元，复合年增长率为12.19%，到2030年将达到182亿美元。

主要市场统计数据
基准年 2023 年 81.3亿美元
预计 2024 年 90.6亿美元
预测年份 2030 182亿美元
复合年增长率（%） 12.19％

生物共轭市场正处于变革时代的前沿，推动力来自创新技术的整合和各领域的应用扩展。本报告回顾了生物共轭技术的发展，并强调了该科学在药物开发、诊断和研究中日益增长的重要性。近年来，突破为新方法铺平了道路，使得更灵敏、更具选择性和效率的结合方法成为可能，这些方法将成为下一代治疗和诊断工具的支柱。

在如此动态的环境中，学术机构、生技公司、受託研究机构和製药公司等相关人员受益于强大的生物共轭策略。随着精度提高、性能增强和成本优化的趋势明显，该行业正在采用更全面的研发方法。这项新重点不仅将激发创新，还将培养多学科团队之间的协作精神，为有可能重新定义现代医学的开创性贡献奠定基础。

变革性转变塑造生物共轭格局

近年来，生物共轭的环境发生了显着变化。这些转变的特点是数位化、对研发的大量投资以及先进分析方法的整合。从传统的结合技术到更可靠、更有效的生物正交反应、点击化学和酶促方法的演变证明了市场对科学进步的应对力。

技术创新很快就带来了产品供应和最终用户应用的策略调整。全球产业参与者越来越多地转向专门的试剂、套件和服务模式来支援复杂的製造流程，包括 ADC 製程开发和原料药製造。这些转换不仅提高了共轭精度，而且还带来了更高水准的可扩展性和可重复性。对稳健製程开发和分析验证的日益重视，有助于公司满足监管机构的多方面需求，并使其策略与治疗和诊断应用的长期前景保持一致。

此外，点击化学和基于酶的方法的改进凸显了向减少副反应和提高产品稳定性的方法的转变。这些进步使研究人员能够探索新的标靶机制并优化有效载荷运送，最终加速从概念到市场的进程。简而言之，产业相关人员必须不断适应，在创新是成功主要驱动力的环境中保持竞争优势。

塑造市场动态的详细细分洞察

对市场区隔的考察揭示了生物共轭领域的复杂性和深度。市场根据生物共轭类型、产品、技术、产品类型、最终用户、应用和治疗领域进行细分。涵盖的生物共轭类型包括寡核苷酸生物共轭（包括双链和单链核苷酸）、胜肽生物共轭、聚合物生物共轭和蛋白质生物共轭。每种类型都针对特定的研究需求或临床应用而量身定制，为各种实验挑战提供有针对性的解决方案。

细分市场的分析包括试剂和套件、ADC 製程开发、分析开发、原料药製造、早期开发生物共轭服务、有效载荷和连接体製造、标靶剂或载体蛋白服务等广泛的服务。提供如此广泛的服务凸显了对能够客製化以满足客户独特需求的多功能、专业化产品的需求。

基于技术的分割的讨论扩展到酰胺键形成、生物正交反应、点击化学、酶促方法和硫醇-马来酰亚胺偶联等方法。这些技术体现了创新化学和生物化学对提高产品性能同时确保安全性和可靠性的持续贡献。

此外，我们区分了天然和合成的生物共轭物，并表明每个类别都符合特定的功能和监管要求。除此之外，还有基于最终用户的细分市场，例如学术和研究机构、生物技术公司、受託研究机构和製药公司，每个细分市场都有自己的优先事项和营运框架。

应用为市场区隔提供了另一个维度。生物共轭平台有多种用途，包括诊断、研究和开发以及治疗应用。特别是治疗应用，进一步分为抗生素、单株抗体和疫苗，展现出由解决复杂临床挑战的努力所推动的强劲图景。

最后，基于治疗领域的细分主要集中在心血管疾病、免疫学、感染疾病和肿瘤学，反映了生物共轭技术的广泛影响。这些细分维度之间的相互作用有助于行业相关人员优化其投资组合，并开发高度针对性的产品以满足不断变化的市场需求。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 生物製剂和抗体药物复合体(ADC) 的使用激增
    • 限制因素
      • 生物共轭研究的成本密集度和先进研究设备的初始投资
    • 机会
      • 生物共轭物合成进展
      • 增加公共和私营部门对生物共轭能力的投资
    • 任务
      • 对维持生物共轭物生产中的一致性和品管的担忧
  • 市场区隔分析
    • 治疗领域：生物共轭透过改善治疗的传递和疗效，在心血管疾病方面具有巨大优势
    • 生物共轭类型：单链寡核苷酸因其在治疗性介入中的多功能性而变得重要
    • 提供：键合製程的复杂设计和最佳化增强了 ADC 製程开发服务的可能性。
    • 技术：酰胺键形成技术由于其可靠性和所得结合物的强度而越来越被采用
    • 类型：合成生物共轭物由于其稳定性和可自订性而变得越来越重要
    • 最终用户：生物技术公司越来越多地采用生物共轭来提高其生物製药产品的功效和特异性。
    • 应用：透过准确辨识癌细胞和肿瘤特异性抗原，生物共轭技术在癌症诊断中已广泛应用
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会的
    • 技术的
    • 合法的
    • 环境

第六章 生物共轭市场依生物共轭型划分

  • 寡核苷酸生物共轭
    • 双链核苷酸
    • 单链核苷酸
  • 肽生物共轭
  • 聚合物生物共轭
  • 蛋白质生物共轭

第七章 生物共轭市场依产品分类

  • 试剂和套件
  • 服务
    • ADC 製程开发
    • 分析与开发
    • 医药原料製造
    • 早期开发生物共轭服务
    • 有效载荷和链接器生产
    • 标靶药物或载体蛋白服务

第 8 章。

  • 酰胺键形成
  • 生物正交反应
  • 点击化学
  • 酵素法
  • 硫醇-马来酰亚胺偶联

第九章 生物共轭市场按类型

  • 天然生物复合物
  • 合成生物共轭物

第 10 章 生物共轭市场（依最终用户划分）

  • 学术和研究机构
  • 生技公司
  • 合约研究组织
  • 製药公司

第 11 章 生物共轭市场（依应用）

  • 诊断
  • 研究与开发
  • 治疗
    • 抗生素
    • 单株抗体
    • 疫苗

第 12 章 生物共轭市场（依治疗领域）

  • 心血管疾病
  • 免疫学
  • 感染疾病
  • 肿瘤学

第 13 章：美洲生物共轭市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

14. 亚太地区生物共轭市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 15 章欧洲、中东和非洲生物共轭市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章 竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • AbbVie Inc.
  • Abcam plc by Danaher Corporation
  • Abzena Limited
  • Agilent Technologies, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bio-Techne Corporation
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Charles River Laboratories International, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Innovagen AB
  • Johnson & Johnson Services Inc
  • Lonza Group AG
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi SA
  • Sartorius AG
  • Sorrento Therapeutics, Inc.
  • Sutro Biopharma, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd
Product Code: MRR-1B650A7892A1

The Bioconjugation Market was valued at USD 8.13 billion in 2023 and is projected to grow to USD 9.06 billion in 2024, with a CAGR of 12.19%, reaching USD 18.20 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 8.13 billion
Estimated Year [2024] USD 9.06 billion
Forecast Year [2030] USD 18.20 billion
CAGR (%) 12.19%

The bioconjugation market is at the forefront of a transformative era, marked by a fusion of innovative technologies and expanding applications across various fields. This report outlines the evolution of bioconjugation techniques and highlights the increasing importance of this science in drug development, diagnostics, and research. Over the past few years, breakthrough advancements have paved the way for new methodologies, enabling more sensitive, selective, and efficient conjugation methods that serve as the backbone for next-generation therapeutics and diagnostic tools.

In this dynamic environment, stakeholders from academic institutions, biotechnology firms, contract research organizations, and pharmaceutical companies are reaping the benefits of robust bioconjugation strategies. With clear trends toward precision, enhanced performance, and cost optimization, the industry now embraces a more integrated approach to research and development. This renewed focus not only encourages innovation but also drives the collaborative spirit among multidisciplinary teams, setting the stage for groundbreaking contributions that hold the potential to redefine modern medicine.

Transformative Shifts Driving the Bioconjugation Landscape

Recent years have witnessed transformative shifts in the bioconjugation landscape. These shifts are predominantly characterized by digitization, focused investments in research and development, and the integration of advanced analytical methods. The evolution from traditional conjugation techniques to more reliable and efficient bio-orthogonal reactions, click chemistry, and enzymatic methods is a testament to the market's responsiveness to scientific advancements.

Technological innovation has been quickly followed by strategic realignment in product offerings and end-user applications. Global industry players are increasingly moving towards specialized reagents, kits, and service models that support complex manufacturing processes, including ADC process development and drug substance manufacturing. These transformative changes have not only improved the precision of conjugation but have also led to higher levels of scalability and reproducibility. The emphasis on robust process development and analytical validation means that companies can now address the multifaceted demands of regulatory bodies and align their strategies with the long-term outlook of therapeutic and diagnostic applications.

Furthermore, the ongoing improvements in click chemistry and enzyme-based techniques underscore the shift towards methodologies that offer reduced side reactions and enhanced product stability. This evolution is enabling researchers to explore novel targeting mechanisms and optimize payload delivery, ultimately accelerating the pathway from concept to market. In essence, industry participants must continuously adapt to maintain competitive advantage in a landscape where innovation is the primary driver of success.

Detailed Segmentation Insights Shaping Market Dynamics

A close examination of market segmentation reveals the complexity and depth of the bioconjugation sector. The market has been delineated based on bioconjugation type, offering, technique, product type, end user, applications, and therapeutic areas. In terms of bioconjugation type, the focus ranges from oligonucleotide bioconjugation, which encompasses both double-stranded and single-stranded oligonucleotides, to peptide bioconjugation, polymer bioconjugation, and protein bioconjugation. Each type is tailored to specific research needs and clinical applications, ensuring that targeted solutions are available for diverse experimental challenges.

When analyzing the offering, the market segments include reagents and kits, as well as a wide range of services such as ADC process development, analytical development, drug substance manufacturing, early development bioconjugate services, payload and linker manufacturing, and targeting agent or carrier protein services. This broad offering spectrum highlights the need for versatile and specialized products that can be customized to address unique client demands.

Technique-based segmentation extends the discussion to include methods such as amide bond formation, bio-orthogonal reactions, click chemistry, enzymatic methods, and thiol-maleimide coupling. These techniques illustrate the ongoing contribution of innovative chemistry and biochemistry in enhancing product performance while ensuring safety and reliability.

Furthermore, another layer of segmentation distinguishes natural bioconjugates from synthetic bioconjugates, with each category meeting specific functional and regulatory requirements. This is complemented by segments based on the end user, which include academic and research institutions, biotechnology companies, contract research organizations, and pharmaceutical companies, each with unique priorities and operational frameworks.

Applications provide yet another dimension to market segmentation. The bioconjugation platform supports a multitude of purposes including diagnostics, research and development, and therapeutic applications. Therapeutic applications, in particular, have been further divided into antibiotics, monoclonal antibodies, and vaccines, revealing a robust landscape fueled by effort to address complex clinical challenges.

Finally, segmentation based on therapeutic areas looks at cardiovascular disorders, immunology, infectious diseases, and oncology, reflecting the wide-ranging impact of bioconjugation technologies. The interplay between these segmented dimensions empowers industry stakeholders to optimize their portfolios and create highly targeted offerings that cater to evolving market demands.

Based on Bioconjugation Type, market is studied across Oligonucleotide Bioconjugation, Peptide Bioconjugation, Polymer Bioconjugation, and Protein Bioconjugation. The Oligonucleotide Bioconjugation is further studied across Double-Stranded Oligonucleotides and Single-Stranded Oligonucleotides.

Based on Offering, market is studied across Reagents & Kits and Services. The Services is further studied across ADC Process Development, Analytical development, Drug Substance Manufacturing, Early Development Bioconjugate Services, Payload & Linker Manufacturing, and Targeting Agent or Carrier Protein Services.

Based on Technique, market is studied across Amide Bond Formation, Bio-orthogonal Reactions, Click Chemistry, Enzymatic Methods, and Thiol-Maleimide Coupling.

Based on Type, market is studied across Natural Bioconjugates and Synthetic Bioconjugates.

Based on End User, market is studied across Academic & Research Institutions, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies.

Based on Applications, market is studied across Diagnostics, Research and Development, and Therapeutic. The Therapeutic is further studied across Antibiotics, Monoclonal Antibodies, and Vaccines.

Based on Therapeutic Areas, market is studied across Cardiovascular Disorders, Immunology, Infectious Diseases, and Oncology.

Key Regional Insights Unveiling Global Market Trends

The bioconjugation market exhibits significant regional variation, with key insights drawn from extensive research across major regions. In the Americas, the presence of advanced research infrastructures coupled with strong investments in biotech innovation fosters an environment conducive to pioneering therapeutic advancements and novel conjugation methodologies. The rigorous regulatory frameworks and favorable funding opportunities in this region provide a steady platform for industry growth and cutting-edge research.

Progress in Europe, the Middle East, and Africa is marked by robust academic-industry collaborations, a rich legacy in pharmaceutical sciences, and increasing support for innovation. European nations have consistently taken strides in driving regulatory excellence, which in turn has catalyzed the development of sophisticated bioconjugate products. In parallel, the Middle East and Africa are emerging as influential hubs, nurturing strategic partnerships and scaling up research initiatives that promise to impact the wider global market landscape.

The Asia-Pacific region represents a rapidly expanding market, characterized by increasing investments in biotech research, state-of-the-art manufacturing facilities, and a growing emphasis on regulatory harmonization. The region's emphasis on cost-effective manufacturing and scalability positions it as a critical player in global supply chains, especially as demand for high-quality bioconjugation products escalates. This diverse geographical spread highlights the significant role of regional trends in shaping global market dynamics, driving both competitive opportunities and collaborative ventures among industry leaders.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Pioneering Bioconjugation Market Developments

A multitude of established companies continue to influence the bioconjugation market significantly through extensive research, innovative product development, and strategic partnerships. Notable contributions have come from organizations such as AbbVie Inc. and Abcam plc by Danaher Corporation, whose research initiatives have spurred advancements in bioconjugation reagents and analytical precision. By focusing on breakthrough technologies in peptide and protein bioconjugation, these companies have also set new benchmarks for efficiency and reliability.

Other industry giants including Abzena Limited, Agilent Technologies, Inc., Amgen Inc., and AstraZeneca PLC have played pivotal roles in expanding the range of available techniques such as click chemistry and enzymatic methods. Their significant investments in ADC process development and early-stage bioconjugate services have not only accelerated product timelines but also improved the overall therapeutic efficacy.

Organizations like Bio-Techne Corporation, Biocon Limited, Boehringer Ingelheim GmbH, and Bristol-Myers Squibb Company are also actively engaged in refining methodologies and introducing innovative payload strategies. This is complemented by contributions from industry leaders like Charles River Laboratories International, Inc., Eli Lilly and Company, and F. Hoffmann-La Roche AG, whose collaborative industry insights have brought enhanced reliability in drug substance manufacturing and analytical development.

GlaxoSmithKline plc, Innovagen AB, Johnson & Johnson Services Inc., Lonza Group AG, and Merck KGaA further exemplify the diversified efforts in optimizing bioconjugation techniques for various modern therapeutic applications. The continuous evolution of the market is also reflecting in pioneering activities from Pfizer Inc., Sanofi S.A., Sartorius AG, Sorrento Therapeutics, Inc., Sutro Biopharma, Inc., Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd., whose endeavours in cutting-edge research have become central to redefining the standards of quality and performance in the field.

These key companies illustrate the strength of the competitive environment where deep technical expertise meets innovative product strategies, forming the backbone of industry progress and setting a path toward sustained market growth.

The report delves into recent significant developments in the Bioconjugation Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abcam plc by Danaher Corporation, Abzena Limited, Agilent Technologies, Inc., Amgen Inc., AstraZeneca PLC, Bio-Techne Corporation, Biocon Limited, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Charles River Laboratories International, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Innovagen AB, Johnson & Johnson Services Inc, Lonza Group AG, Merck KGaA, Pfizer Inc., Sanofi S.A., Sartorius AG, Sorrento Therapeutics, Inc., Sutro Biopharma, Inc., Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to adopt a proactive approach that integrates robust R&D initiatives with agile business models. It is imperative to invest in advanced bioconjugation techniques and to continuously evaluate the efficiency of established processes such as click chemistry and enzymatic methodologies. Companies should consider forging strategic alliances that bridge academic insights with commercial innovation, thus ensuring a streamlined process from conception to regulatory approval.

Optimizing production capacities through scalable manufacturing platforms and fostering a culture of continuous improvement will help mitigate production risks. Leaders should prioritize portfolio diversification across various product types, including both synthetic and natural bioconjugates, and also tailor solutions to meet the distinct requirements of multiple end-user groups ranging from academic research centers to large pharmaceutical organizations.

Furthermore, a targeted approach focused on regional market trends can yield substantial strategic benefits. For instance, embracing innovations developed in regions with advanced technological infrastructures, while also seeking opportunities in emerging markets, can dynamically improve market reach and capitalize on latent demand.

In addition, it is recommended to refine process development capabilities in areas such as ADC process development, drug substance manufacturing, and analytical validation. This ensures regulatory compliance and enhances the overall commercial viability of bioconjugation products. Ultimately, leaders who balance innovative pursuits with strategic operational adjustments will be best positioned to capture rapidly growing market opportunities and foster long-term industry leadership.

Concluding Reflections on the Future of Bioconjugation

As the bioconjugation market continues to evolve, this report highlights key themes that will shape its future. The interplay of advanced conjugation techniques, diversified segmentation, and regional strategies underscores the market's robust potential for growth and innovation. Stakeholders across the board-from academic and research institutions to pharmaceutical and biotechnology companies-are embracing technological advancements and strategic partnerships to drive market momentum.

Key observations reveal that the shift towards more efficient, reliable, and scalable conjugation methods is no longer optional but essential to remain competitive. Enhanced product offerings, meticulous segmentation analysis, and a clear understanding of global regional dynamics are crucial for navigating the complex bioconjugate ecosystem. The continuous evolution in both product and service dimensions is not only indicative of current market demands but also a harbinger of future advancements.

This concluding analysis reinforces the idea that innovation is at the heart of market progress. By integrating best practices from diverse sectors and focusing on continuous improvement, industry players can drive sustainable growth. The strategic alignment of R&D initiatives with commercial objectives will serve as a catalyst for future success, ensuring that the bioconjugation market remains at the cutting edge of scientific and technological innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in the use of biotherapeutics & antibody-drug conjugates (ADC)
    • 5.1.2. Restraints
      • 5.1.2.1. Cost-intensive nature of bioconjugation research and the initial investment for advanced research equipment
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements for synthesizing the bioconjugates
      • 5.1.3.2. Growing investment from public & private sector in bioconjugation capabilities
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with maintaining consistency and quality control in bioconjugate manufacturing
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapeutic Areas: Significant benefits of bioconjugation in cardiovascular owing to improved delivery and efficacy of therapeutic
    • 5.2.2. Bioconjugation Type: Growing significance of single-stranded oligonucleotides due to enhanced versatility in therapeutic interventions
    • 5.2.3. Offering: Rising potential of ADC process development services owing to intricate design and optimization of conjugation processes
    • 5.2.4. Technique: Increased adoption of amide bond formation technique due to reliability and the strength of the resulting conjugates
    • 5.2.5. Type: Growing significance of synthetic bioconjugates due to their stability and customization capabilities
    • 5.2.6. End User: Emerging incorporation of bioconjugation in biotechnology companies to enhance the efficacy and specificity of their biopharmaceutical products
    • 5.2.7. Applications: Proliferation of bioconjugation in cancer diagnostics owing to precise identification of cancerous cells and tumor-specific antigens
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bioconjugation Market, by Bioconjugation Type

  • 6.1. Introduction
  • 6.2. Oligonucleotide Bioconjugation
    • 6.2.1. Double-Stranded Oligonucleotides
    • 6.2.2. Single-Stranded Oligonucleotides
  • 6.3. Peptide Bioconjugation
  • 6.4. Polymer Bioconjugation
  • 6.5. Protein Bioconjugation

7. Bioconjugation Market, by Offering

  • 7.1. Introduction
  • 7.2. Reagents & Kits
  • 7.3. Services
    • 7.3.1. ADC Process Development
    • 7.3.2. Analytical development
    • 7.3.3. Drug Substance Manufacturing
    • 7.3.4. Early Development Bioconjugate Services
    • 7.3.5. Payload & Linker Manufacturing
    • 7.3.6. Targeting Agent or Carrier Protein Services

8. Bioconjugation Market, by Technique

  • 8.1. Introduction
  • 8.2. Amide Bond Formation
  • 8.3. Bio-orthogonal Reactions
  • 8.4. Click Chemistry
  • 8.5. Enzymatic Methods
  • 8.6. Thiol-Maleimide Coupling

9. Bioconjugation Market, by Type

  • 9.1. Introduction
  • 9.2. Natural Bioconjugates
  • 9.3. Synthetic Bioconjugates

10. Bioconjugation Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutions
  • 10.3. Biotechnology Companies
  • 10.4. Contract Research Organizations
  • 10.5. Pharmaceutical Companies

11. Bioconjugation Market, by Applications

  • 11.1. Introduction
  • 11.2. Diagnostics
  • 11.3. Research and Development
  • 11.4. Therapeutic
    • 11.4.1. Antibiotics
    • 11.4.2. Monoclonal Antibodies
    • 11.4.3. Vaccines

12. Bioconjugation Market, by Therapeutic Areas

  • 12.1. Introduction
  • 12.2. Cardiovascular Disorders
  • 12.3. Immunology
  • 12.4. Infectious Diseases
  • 12.5. Oncology

13. Americas Bioconjugation Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Bioconjugation Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Bioconjugation Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Lonza expands U.S. biologics capacity with USD 1.2 Billion acquisition of Roche's vacaville site
    • 16.3.2. Abzena expands partnership with proteoNic to standardize 2G UNic technology
    • 16.3.3. Abzena invests USD 5 million to enhance bioconjugation and ADC capacities at bristol facility
    • 16.3.4. WuXi XDC Commences construction of Singapore facility to boost bioconjugate development
    • 16.3.5. AstraZeneca's strategic acquisition of Fusion Pharmaceuticals to enhance Radioconjugate cancer therapies
    • 16.3.6. Samsung Biologics and LegoChem Biosciences collaborate on antibody-drug conjugate development
    • 16.3.7. Novo holdings strategic acquisition of Catalent to enhance bioconjugation capabilities
    • 16.3.8. OnCusp Therapeutics garners USD 100M Series A funding for advancing CUSP06 ADC and expanding oncology innovations
    • 16.3.9. Piramal Pharma Solutions boosts global bioconjugation capabilities with Pound 45 million ADC expansion
    • 16.3.10. GeneQuantum and BioMap partner to revolutionize ADC therapeutics with AI-driven bioconjugation
    • 16.3.11. Nona Biosciences and GeneQuantum partner to advance next-gen bioconjugate drug discovery
  • 16.4. Strategy Analysis & Recommendation
    • 16.4.1. WuXi AppTec Co., Ltd
    • 16.4.2. Lonza Group AG
    • 16.4.3. Merck KGaA
    • 16.4.4. Thermo Fisher Scientific Inc.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Abcam plc by Danaher Corporation
  • 3. Abzena Limited
  • 4. Agilent Technologies, Inc.
  • 5. Amgen Inc.
  • 6. AstraZeneca PLC
  • 7. Bio-Techne Corporation
  • 8. Biocon Limited
  • 9. Boehringer Ingelheim GmbH
  • 10. Bristol-Myers Squibb Company
  • 11. Charles River Laboratories International, Inc.
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche AG
  • 14. GlaxoSmithKline plc
  • 15. Innovagen AB
  • 16. Johnson & Johnson Services Inc
  • 17. Lonza Group AG
  • 18. Merck KGaA
  • 19. Pfizer Inc.
  • 20. Sanofi S.A.
  • 21. Sartorius AG
  • 22. Sorrento Therapeutics, Inc.
  • 23. Sutro Biopharma, Inc.
  • 24. Thermo Fisher Scientific Inc.
  • 25. WuXi AppTec Co., Ltd

LIST OF FIGURES

  • FIGURE 1. BIOCONJUGATION MARKET MULTI-CURRENCY
  • FIGURE 2. BIOCONJUGATION MARKET MULTI-LANGUAGE
  • FIGURE 3. BIOCONJUGATION MARKET RESEARCH PROCESS
  • FIGURE 4. BIOCONJUGATION MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL BIOCONJUGATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOCONJUGATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOCONJUGATION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOCONJUGATION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BIOCONJUGATION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BIOCONJUGATION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES BIOCONJUGATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES BIOCONJUGATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. BIOCONJUGATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. BIOCONJUGATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOCONJUGATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOCONJUGATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOCONJUGATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOCONJUGATION MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOCONJUGATION MARKET SIZE, BY DOUBLE-STRANDED OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOCONJUGATION MARKET SIZE, BY SINGLE-STRANDED OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOCONJUGATION MARKET SIZE, BY PEPTIDE BIOCONJUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOCONJUGATION MARKET SIZE, BY POLYMER BIOCONJUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOCONJUGATION MARKET SIZE, BY PROTEIN BIOCONJUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOCONJUGATION MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOCONJUGATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOCONJUGATION MARKET SIZE, BY ADC PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOCONJUGATION MARKET SIZE, BY ANALYTICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOCONJUGATION MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOCONJUGATION MARKET SIZE, BY EARLY DEVELOPMENT BIOCONJUGATE SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOCONJUGATION MARKET SIZE, BY PAYLOAD & LINKER MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOCONJUGATION MARKET SIZE, BY TARGETING AGENT OR CARRIER PROTEIN SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOCONJUGATION MARKET SIZE, BY AMIDE BOND FORMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIO-ORTHOGONAL REACTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOCONJUGATION MARKET SIZE, BY CLICK CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOCONJUGATION MARKET SIZE, BY ENZYMATIC METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOCONJUGATION MARKET SIZE, BY THIOL-MALEIMIDE COUPLING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOCONJUGATION MARKET SIZE, BY NATURAL BIOCONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOCONJUGATION MARKET SIZE, BY SYNTHETIC BIOCONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOCONJUGATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOCONJUGATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOCONJUGATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BIOCONJUGATION MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOCONJUGATION MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOCONJUGATION MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL BIOCONJUGATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOCONJUGATION MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL BIOCONJUGATION MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOCONJUGATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL BIOCONJUGATION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOCONJUGATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES BIOCONJUGATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 204. SINGAPORE BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 224. TAIWAN BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 234. THAILAND BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 244. VIETNAM BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 265. DENMARK BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 275. EGYPT BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 285. FINLAND BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 295. FRANCE BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 303. GERMANY BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 304. GERMANY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 305. GERMANY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 313. ISRAEL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 314. ISRAEL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 315. ISRAEL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 323. ITALY BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 324. ITALY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 325. ITALY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 334. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 340. NIGERIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 341. NIGERIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 342. NIGERIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 343. NIGERIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 344. NIGERIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 345. NIGERIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 350. NORWAY BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 351. NORWAY BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 352. NORWAY BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 353. NORWAY BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 354. NORWAY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 355. NORWAY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 356. POLAND BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. POLAND BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 358. POLAND BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 359. POLAND BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 360. POLAND BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 361. POLAND BIOCONJUGATION MARKET SIZE, BY TYPE, 20